Oral Roflumilast for Long-term Management of Behçet Spectrum Disorders: A Multicenter Observational Analysis
Roflumilast is effective for managing BSD, offering a safe option to address unmet needs in RAS and BD. Its favorable safety profile and long-term efficacy support its use in the routine clinical practice.
Authors
- M. Linares‐Barrios (ORCID: https://orcid.org/0000-0001-5048-8524)
- L. Bagan
- Ángel González García (ORCID: https://orcid.org/0009-0001-5071-9369)
- C. Labrandero Hoyos
- Rodrigo Peñuelas Leal (ORCID: https://orcid.org/0000-0002-9627-780X)
- José Vicente Bagán Sebastián (ORCID: https://orcid.org/0000-0002-0295-2916)
- Malena Finello (ORCID: https://orcid.org/0000-0003-0711-3481)
- Andrés Grau Echevarría (ORCID: https://orcid.org/0000-0003-2557-3107)
- Luis G. Fernández
- Daniel Blaya Imbernón (ORCID: https://orcid.org/0009-0002-7667-600X)
- Elena Pérez Zafrilla
- Violeta Zaragozá Ninet
- V. Alegre de Miquel
- J C Ruiz
- Gemma Pérez Pastor
- Miguel Martí Cabrera
- E. Recio
Institutions
- Universitat de València (ES)
- Hospital Universitari Sant Joan D'Alacant (ES)
- Association of Electronic and Information Technologies (ES)
- Hospital General Universitario De Valencia (ES)
- Hospital Universitario Puerta del Mar (ES)
Publication Details
- Journal
- Actas Dermo-Sifiliográficas
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1016/j.ad.2025.104561
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00